Table III.

Specific antibody response against spike (S1-S2) and receptor-binding domain (RBD) antigens in 29 IEI patients with severe/critical COVID-19

Patient ID	IEI	Days after onset of infection	S1-S2			RBD
			IgM AU/mL (1:3200)	IgA AU/mL (1:1600)	IgG AU/mL (1:6400)	IgM AU/mL (1:1600)	IgA AU/mL (1:1600)	IgG AU/mL (1:1600)
Cutoff	—	—	2.5	0.5	0.03	8.4	0.08	14.8
P1	Hyper-IgM syndrome	21	38.31∗	0	0	14.86∗	0	3.84
P2	Immune dysregulation	7	0	0	0	0	0	0
P3	Immune dysregulation	9	109.47∗	17.67∗	84.58∗	128.24∗	18.12∗	955.60∗
P4	Innate immunodeficiency	5	5.18∗	24.51∗	1.09∗	5.60	27.22∗	20.46∗
P5	CID	8	44.25∗	23.18∗	21.10∗	109.35∗	11.30∗	120.40∗
P6	CID	9	0	0	1.91∗	0	0	19.76∗
P7	Innate immunodeficiency	7	0	0	43.54∗	0	0	246.61∗
P8	Immune dysregulation	7	0	0	0	0	0	0
P9	Immune dysregulation	5	40.53∗	4.54∗	6.39∗	37.83∗	0	33.05∗
P10	CID	8	30.39∗	0	0	19.00∗	0	19.76∗
P11	CID	4	0	0	2.29∗	0	0	0
P12	Innate immunodeficiency	9	0	0	0	0	0	0
P13	Autoinflammatory disorders	7	0	0	0	0	0	0
P14	CID	15	67.80∗	28.86∗	213.05∗	66.55∗	8.20∗	0
P15	Immune dysregulation	10	61.91∗	52.01∗	171.67∗	67.08∗	87.54∗	0
P16	Innate immunodeficiency	16	85.08∗	40.10∗	62.07∗	41.37∗	29.34∗	359.96∗
P17	Autoinflammatory disorders	13	42.65∗	31.87∗	99.23∗	13.66∗	19.75∗	531.38∗
P18	CID	11	102.05∗	103.97∗	79.31∗	96.75∗	33.59∗	467.53∗
P19	Innate immunodeficiency	14	0	0	0	0	0	0
P20	SCID	9	0	0	17.56∗	0	0	22.56∗
P21	Immune dysregulation	8	0.94	0	0	2.24	0	9.59
P22	Innate immunodeficiency	8	0	0	0	0	0	0
P23	Immune dysregulation	7	38.93∗	0	0	40.29∗	0	22.56∗
P24	Autoinflammatory disorders	8	0	0	0	1.10	0	23.26∗
P25	CID	8	37.34∗	12.58∗	4.02∗	14.56∗	1.19∗	29.55∗
P26	Innate immunodeficiency	10	0	0	0	0	0	0
P27	Innate immunodeficiency	9	2.75∗	0	0	0	0	5.59
P28	SCID/CID	21	0	0	0	0	0	6.93
P29	Agammaglobulinemia	27	0	0	0	0	0	0

Cutoff determined on the basis of negative controls collected before pandemic time and the cohort of PCR-confirmed COVID-19 patients with no known IEI.³⁹SCID, Severe CID.

^∗Positive sample.